Oligohydramnios and pulmonary hypoplasia: A case in which involvement of an angiotensin II receptor antagonist was suspected

Journal of Obstetrics and Gynaecology Research

Volumn 34, Issue 2, 2008, Pages 242-246

  Kato, Kaoru ^a   Okuda, Mika ^a   Ishikawa, Hiroshi ^a   Takahashi, Tsuneo ^a   Hirahara, Fumiki ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Angiotensin II receptor antagonist; Fetus; Oligohydramnios; Pregnancy; Renal damage

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; FUROSEMIDE; NIFEDIPINE;

ADULT; ARTICLE; AUTOPSY; BIRTH; BODY WEIGHT; CASE REPORT; DELIVERY; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; FEMALE; FIRST TRIMESTER PREGNANCY; HEALTH CENTER; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DISORDER; LUNG HYPOPLASIA; LUNG WEIGHT; MOTHER; NEPHROTIC SYNDROME; OLIGOHYDRAMNIOS; PREGNANCY TERMINATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; DIABETIC NEPHROPATHIES; FATAL OUTCOME; FEMALE; HUMANS; HYPERTENSION; INFANT, NEWBORN; LUNG; OLIGOHYDRAMNIOS; PREGNANCY; PREGNANCY IN DIABETICS; TETRAZOLES;

EID: 42149163520     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2008.00762.x     Document Type: Article

References (17)

1. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: Target for drug research? J Hypertens Suppl 1994 12 : S1 S5.
2. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999 33 : 613 621.
3. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998 83 : 1182 1191.
4. Schaefer C. Angiotensin II receptor-antagonists: Further evidence of fetotoxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol 2003 67 : 591 594.
5. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res Part A Clin Mol Teratol 2005 73 : 123 130.
6. Hulton SA, Thomson PD, Cooper PA, Rothberg AD. Angiotensin-converting enzyme inhibitors in pregnancy may result in neonatal renal failure. S Afr Med J 1990 78 : 673 676.
7. Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects. Lancet 2001 357 : 363.
8. Lambot MA, Vermeylen D, Noël JC. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001 357 : 1619 1620.
9. Hinsberger A, Wingen AM, Hoyer PF. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001 357 : 1620.
10. Martinovic J, Bebachi A, Laurent N, Daikha-Dahmane F, Gubler MC. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 2001 358 : 241 242.
11. Briggs GG, Nageotte MP. Fetal outcome with the combinated use of valsartan and atenolol. Ann Pharmacother 2001 35 : 859 861.
12. Cox RM, Anderson JM, Cox P. Defective embryogenesis with angiotensin II receptor antagonists in pregnancy. Br J Obstet Gynaecol 2003 110 : 1038 1040.
13. Bos-Thompson MA, Hillaire-Buys D, Muller F et al. Fetal toxic effects of angiotensin II receptor antagonists. Ann Pharmacother 2005 39 : 157 161.
14. Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res Part A Clin Mol Teratol 2004 70 : 547 549.
15. Vendemmia M, Garcia-Meric P, Rizzotti A et al. Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II-receptor- antagonists. J Mater Fetal Neonatal Med 2005 18 : 137 140.
16. Daïkha-Dahmane F, Levy-Beff E, Jugie M, Lenclen R. Foetal kidney maldevelopment in maternal use of Angiotensin II type 1 receptor-antagonists. Pediatr Nephrol 2006 21 : 729 732.
17. Serreau R, Luton D, Macher MA, Delezoide AL, Garel C, Jacqz-Aigrain E. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: A report of 10 cases. Br J Obstet Gynaecol 2005 112 : 710 712.